Adverse Drug Reactions Related to Drug Administration in Hospitalized Patients

Gallelli, Luca; Siniscalchi, Antonio; Palleria, Caterina; Mumoli, Laura; Staltari, Orietta; Squillace, Aida; Maida, Francesca; Russo, Emilio; Gratteri, Santo; Sarro, Giovambattista De

doi:10.2174/1574886312666170616090640

Cited by 21 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with our previous studies [19][20][21][22], using the Naranjo probability scale, we documented a possible association between severe panniculitis and panitumumab in two women with mCRC (Naranjo score 6) that required a treatment with corticosteroids and empirical antimicrobial drugs.…”

Section: Discussionsupporting

confidence: 92%

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer

Ciliberto

Ierardi

Caroleo

et al. 2019

CDS

Self Cite

View full text Add to dashboard Cite

Background: Panitumumab is an EGFR inhibitor used for the treatment of metastatic colorectal cancer (mCRC), even if its use is related to skin toxicity. Case Presentation: We report the development of forearm panniculitis in two women during the treatment with Panitumumab (6 mg/Kg intravenous every 2 weeks) + FOLFOX-6 (leucovorin, 5- fluorouracil, and oxaliplatin at higher dosage) for the treatment of mCRC. Results: In both patients, clinical, laboratory and radiological evaluation documented the presence of a local panniculitis, probably related to panitumumab (Naranjo score: 6). Panatimumab discontinuation and antimicrobial + corticosteroid treatment induced a remission of skin manifestations. Conclusion: We reported for the first time the development of panniculitis during Panitumumab treatment, and we documented that the treatment with beta-lactams to either fluoroquinolones or oxazolidinone in the presence of corticosteroid improves clinical symptoms in young patients with mCRC, without the development of adverse drug reactions or drug-drug interactions.

show abstract

Section: Discussionsupporting

confidence: 92%

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer

Ciliberto

Ierardi

Caroleo

et al. 2019

CDS

Self Cite

View full text Add to dashboard Cite

show abstract

“…The development of adverse drug reactions and drug interactions was evaluated during the whole period of the study (T1-T5) in agreement with our previous papers. [11][12][13][14][15][16] End Points…”

Section: Assessment Of Safetymentioning

confidence: 99%

Efficacy and Safety of Elbasvir‐Grazoprevir Fixed Dose in the Management of Polytreated HCV Patients: Evidence From Real‐Life Clinical Practice

Caroleo

Colangelo

Perticone

et al. 2018

The Journal of Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection represents a global public health challenge, and new drugs have been authorized for its treatment. In this study, we evaluated both the clinical efficacy and safety of elbasvir-grazoprevir fixed-dose combination in HCV patients. We performed a prospective single-blind study on patients admitted to the Regional Center for HCV Treatment of the University of Catanzaro from March 1, 2017, to December 31, 2017, in patients >30 years old with a history of chronic HCV infection. During the study period, we enrolled 29 HCV patients (18 women and 11 men; age, 62.5 ± 14 years, range 36-82; HCV-RNA: 2 384 859 ± 2 487 747 IU/mL, range, 60 400 - 8 930 000 IU/mL genotype 1b). In 28 of 29 patients (96.5%) we documented a rapid and complete remission of HCV infection 4 weeks after the beginning of the treatment, while in 1 patient it was reached in 8 weeks. During the study, we did not record any serious adverse drug reaction or drug interaction and no patients discontinued the treatment. However, 4 patients (13.8%) developed an asymptomatic plasma transaminase increase that appeared at 8 weeks after the beginning of the treatment and disappeared 4 weeks later in 3 patients and 8 weeks later in 1 patient. In conclusion, we documented that in real life the development of plasma transaminase increase in 4 elderly women >70 years old, suggesting that more attention must be focused on this age population.

show abstract

“…DDIs are also more frequent in hospitalized patients, patients who stay in the hospital for a longer time, and/or receive more drugs per day [13,[14][15][16]. Hospitalized patients are more likely to be affected by DDIs because of severe and multiple illnesses, comorbid conditions, chronic therapeutic regimens, poly-pharmacy, and frequent modi cation in therapy [17].…”

Section: Introductionmentioning

confidence: 99%

Prevalence of potential drug- drug interactions and associated factors among outpatients and inpatients in Ethiopian Hospitals: a systematic review and Meta-analysis of observational studies

Ayenew

Asmamaw

Issa

2020

Preprint

View full text Add to dashboard Cite

Background: Drug-drug interaction is an emerging threat to public health. Currently, there is an increase in comorbid disease, polypharmacy, and hospitalization in Ethiopia. Thus, the possibility of drug-drug interaction occurrence is high in hospitals. This study aims to summarize the prevalence of potential drug-drug interactions and associated factors in Ethiopian hospitals.Methods: A literature search was performed by accessing legitimate databases in PubMed/MEDLINE, Google Scholar, and Research Gate for English-language publications. To fetch further related topics advanced search was also applied in Science Direct and HINARI databases. The search was conducted on August 3 to 25, 2019. All published articles available online until the day of data collection were considered. Outcome measures were analyzed with Open Meta Analyst and CMA version statistical software. Der Simonian and Laird’s random effect model, I2 statistics, and Logit event rate were also performed.Results: A total of 14 studies remained eligible for inclusion in systematic review and meta-analysis. From the included studies, around 8,717 potential drug-drug interactions were found in 3,259 peoples out of 5,761 patients. The prevalence of patients with potential drug-drug interactions in Ethiopian hospitals was found to be 72.2% (95% confidence interval: 59.1%, 85.3%). Based on severity, the prevalence of major, moderate, and minor potential drug-drug interaction was 25.1%, 52.8%, 16.9%, respectively, also 1.27% for contraindications. The factors associated with potential drug-drug interactions were related to patient characteristics such as polypharmacy, age, comorbid disease, and hospital stay.Conclusions: There is a high prevalence of potential drug-drug interactions in Ethiopian hospitals. Polypharmacy, age, comorbid disease, and hospital stay were the risk factors associated with potential drug-drug interactions.

show abstract

Adverse Drug Reactions Related to Drug Administration in Hospitalized Patients

Cited by 21 publications

References 0 publications

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer

Efficacy and Safety of Elbasvir‐Grazoprevir Fixed Dose in the Management of Polytreated HCV Patients: Evidence From Real‐Life Clinical Practice

Prevalence of potential drug- drug interactions and associated factors among outpatients and inpatients in Ethiopian Hospitals: a systematic review and Meta-analysis of observational studies

Contact Info

Product

Resources

About